GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Genomma Lab Internacional SAB de CV (OTCPK:GNMLF) » Definitions » EPS without NRI

GNMLF (Genomma Lab InternacionalB de CV) EPS without NRI : $0.13 (TTM As of Dec. 2024)


View and export this data going back to 2012. Start your Free Trial

What is Genomma Lab InternacionalB de CV EPS without NRI?

Genomma Lab InternacionalB de CV's earnings per share without non-recurring items for the three months ended in Dec. 2024 was $0.03. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2024 was $0.13.

During the past 12 months, Genomma Lab InternacionalB de CV's average earnings per share (NRI) Growth Rate was 92.90% per year. During the past 3 years, the average earnings per share (NRI) Growth Rate was 18.30% per year. During the past 5 years, the average earnings per share (NRI) Growth Rate was 16.40% per year. During the past 10 years, the average earnings per share (NRI) Growth Rate was 0.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for Genomma Lab InternacionalB de CV's EPS without NRI or its related term are showing as below:

GNMLF' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -4.3   Med: 18.05   Max: 53.5
Current: 18.3

During the past 13 years, Genomma Lab InternacionalB de CV's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 53.50% per year. The lowest was -4.30% per year. And the median was 18.05% per year.

GNMLF's 3-Year EPS without NRI Growth Rate is ranked better than
61.78% of 811 companies
in the Drug Manufacturers industry
Industry Median: 9.1 vs GNMLF: 18.30

Genomma Lab InternacionalB de CV's EPS (Diluted) for the three months ended in Dec. 2024 was $0.02. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 was $0.12.

Genomma Lab InternacionalB de CV's EPS (Basic) for the three months ended in Dec. 2024 was $0.02. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2024 was $0.12.


Genomma Lab InternacionalB de CV EPS without NRI Historical Data

The historical data trend for Genomma Lab InternacionalB de CV's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genomma Lab InternacionalB de CV EPS without NRI Chart

Genomma Lab InternacionalB de CV Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EPS without NRI
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.08 0.08 0.08 0.08 0.12

Genomma Lab InternacionalB de CV Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 0.02 0.04 0.04 0.03

Competitive Comparison of Genomma Lab InternacionalB de CV's EPS without NRI

For the Drug Manufacturers - Specialty & Generic subindustry, Genomma Lab InternacionalB de CV's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genomma Lab InternacionalB de CV's PE Ratio without NRI Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Genomma Lab InternacionalB de CV's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where Genomma Lab InternacionalB de CV's PE Ratio without NRI falls into.


;
;

Genomma Lab InternacionalB de CV EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.13

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Genomma Lab InternacionalB de CV  (OTCPK:GNMLF) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


Genomma Lab InternacionalB de CV EPS without NRI Related Terms

Thank you for viewing the detailed overview of Genomma Lab InternacionalB de CV's EPS without NRI provided by GuruFocus.com. Please click on the following links to see related term pages.


Genomma Lab InternacionalB de CV Business Description

Traded in Other Exchanges
Address
Avenida Antonio Dovali Jaime, Number 70, Tower C, Floor 2, Office A. Colonia Santa Fe, Del. Alvaro Obregon, Mexico, MEX, MEX, CP 01210
Genomma Lab Internacional SAB de CV is a specialty and generic drug manufacturer. The company's stated goal is to improve and preserve the health and well-being of people through innovative, safe, and effective products. Genomma operates a wide variety of brands to serve different consumer needs, including pregnancy, pain medication, and deodorant. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.